Markets

Stock Alert: BioXcel Therapeutics Up 30%

(RTTNews) - Shares of BioXcel Therapeutics, Inc. (BTAI) are currently up nearly 30% on Monday morning trade after the company said that two late-stage trials of treatment for schizophrenia and bipolar disorder met their primary endpoints.

BTAI is currently trading at $67.83, up $14.84 or 28.01%, on the Nasdaq.

BioXcel Therapeutics is a clinical-stage biopharmaceutical company developing drugs utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

BXCL501 was being evaluated in two phase III studies for the acute treatment of agitation in patients with schizophrenia, dubbed SERENITY I, and bipolar disorder, known as SERENITY II.

The company announced that BXCL501 met the primary and secondary endpoints of SERENITY I and SERENITY II, demonstrating a robust treatment effect in the trials.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BTAI

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More